We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
GENO.ST

Price
18.54
Stock movement up
+0.22 (1.20%)
Company name
Genovis AB (publ.)
Exchange
(ST
,
Currency
SEK
)
Sector
Healthcare >
Biotechnology
Market cap
1.21B
Ent value
1.16B
Price/Sales
9.36
Price/Book
5.46
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
43.49
Forward P/E
40.04
PEG
-
EPS growth
-
1 year return
-41.51%
3 year return
-30.98%
5 year return
-4.14%
10 year return
29.80%
Last updated: 2025-04-12

DIVIDENDS

GENO.ST does not pay dividends or no data was received

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E43.49
Price to OCF42.76
Price to FCF45.02
Price to EBITDA43.33
EV to EBITDA41.25

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales9.36
Price to Book5.46
EV to Sales8.91

FINANCIALS

Per share

Loading...
Per share data
Current share count65.47M
EPS (TTM)0.43
FCF per share (TTM)0.41

Income statement

Loading...
Income statement data
Revenue (TTM)129.73M
Gross profit (TTM)48.18M
Operating income (TTM)41.33M
Net income (TTM)27.91M
EPS (TTM)0.43
EPS (1y forward)0.46

Margins

Loading...
Margins data
Gross margin (TTM)37.14%
Operating margin (TTM)31.86%
Profit margin (TTM)21.51%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash155.53M
Net receivables0.00
Total current assets199.34M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets319.35M
Accounts payable0.00
Short/Current long term debt0.00
Total current liabilities22.22M
Total liabilities97.15M
Shareholder's equity222.20M
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)28.39M
Capital expenditures (TTM)1.76M
Free cash flow (TTM)26.96M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity12.56%
Return on Assets8.74%
Return on Invested Capital12.56%
Cash Return on Invested Capital12.13%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open18.72
Daily high18.72
Daily low17.38
Daily Volume94K
All-time high100.25
1y analyst estimate39.00
Beta1.64
EPS (TTM)0.43
Dividend per share-
Ex-div date-
Next earnings date15 May 2025

Downside potential

Loading...
Downside potential data
GENO.STS&P500
Current price drop from All-time high-81.51%-12.89%
Highest price drop-98.90%-56.47%
Date of highest drop7 Apr 20159 Mar 2009
Avg drop from high-78.59%-11.07%
Avg time to new high912 days12 days
Max time to new high4552 days1805 days
COMPANY DETAILS
GENO.ST (Genovis AB (publ.)) company logo
Marketcap
1.21B
Marketcap category
Small-cap
Description
Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics for customers in the pharmaceutical and research industries. The company provides FabALACTICA, a cysteine protease; FabRICATOR, a cysteine protease; and FabRICATOR Z, for the digestion of mouse IgG2a and IgG3, and generating a homogenous pool of F(ab')2 and Fc fragments. It offers FabULOUS (SpeB), a cysteine protease; GingisKHAN, a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. In addition, the company offers GingisREX, a protease that digests proteins C-terminally of arginine residues; GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; OmniGLYZOR, a mixture of immobilized enzymes; PNGase F, a glycoamidase; and OpeRATOR, an O-glycan-specific protease. Further, it provides OglyZOR, an endoglycosidase; SialEXO, a sialidase product; FucosEXO, a mix of a-Fucosidases; GalactEXO, a ß-Galactosidase mix; GalNAcEXO, an a-N-Acetylgalactosaminidase; GlycOCATCH, an affinity resin; GlycINATOR (EndoS2), an IgG-specific endoglycosidase; IgGZERO (EndoS), an IgG-specific endoglycosidase; Anti-FabRICATOR (Anti-IdeS), a goat polyclonal antibody; and Anti-FabRICATOR Z (Anti-IdeZ), a goat polyclonal antibody. Additionally, the company offers antibodies, assay kits, reagents, and cell culture products; bioprocess and gene therapy services; and services, such as SmartEnzymes fragmentation and conjugation, antibody LC-MS analysis, and customized antibody services, as well as operates an online store for its products. It serves pharmaceutical and biotech, contract research, and contract manufacturing companies in Europe, North America, and Asia. The company was founded in 1999 and is headquartered in Kävlinge, Sweden.
Employees
37
Investor relations
-
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found